ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.055 AUD 1.85% Market Closed
Market Cap: 111.3m AUD
Have any thoughts about
ImpediMed Ltd?
Write Note

Operating Margin
ImpediMed Ltd

-205.7%
Current
-203%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-205.7%
=
Operating Profit
-21.2m
/
Revenue
10.3m

Operating Margin Across Competitors

Country AU
Market Cap 111.3m AUD
Operating Margin
-206%
Country US
Market Cap 204.9B USD
Operating Margin
17%
Country US
Market Cap 195.2B USD
Operating Margin
26%
Country US
Market Cap 146.7B USD
Operating Margin
22%
Country US
Market Cap 132.6B USD
Operating Margin
18%
Country IE
Market Cap 110.6B USD
Operating Margin
19%
Country US
Market Cap 64.7B USD
Operating Margin
14%
Country DE
Market Cap 55.6B EUR
Operating Margin
12%
Country CN
Market Cap 319.2B CNY
Operating Margin
37%
Country US
Market Cap 41.6B USD
Operating Margin
28%
Country US
Market Cap 37.7B USD
Operating Margin
13%
No Stocks Found

ImpediMed Ltd
Glance View

Market Cap
111.3m AUD
Industry
Health Care

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

IPD Intrinsic Value
0.079 AUD
Undervaluation 30%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-205.7%
=
Operating Profit
-21.2m
/
Revenue
10.3m
What is the Operating Margin of ImpediMed Ltd?

Based on ImpediMed Ltd's most recent financial statements, the company has Operating Margin of -205.7%.